Annexon presents vonaprument Phase 3 trial plans for geographic atrophy
ANNX•Annexon said its 659-patient ARCHER II trial remains on track for a 15-month primary analysis in Q4 2026. The company also reported that monthly vonaprument reduced the risk of confirmed vision loss of at least 15 letters by 73% versus sham in Phase 2.
1. Trial timelines
Annexon said the Phase 3 ARCHER II trial of vonaprument for geographic atrophy enrolled 659 patients and has statistical power above 90% to assess vision protection. Its 15-month primary analysis is on track for Q4 2026. Two predefined substudies supporting a US filing are planned for 15-month analyses in Q1 2027, with 24-month analyses expected in Q3 2027.
2. Phase 2 results
In Phase 2, monthly vonaprument reduced the risk of confirmed vision loss of at least 15 letters by 73% versus sham.
